| 70.98 0 (0%) | 11-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 82.9 | 1-year : | 96.83 |
| Resists | First : | 70.98 | Second : | 82.9 |
| Pivot price | 70.45 |
|||
| Supports | First : | 70.34 | Second : | 69.95 |
| MAs | MA(5) : | 70.67 |
MA(20) : | 70.41 |
| MA(100) : | 69.11 |
MA(250) : | 67.11 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 87.4 |
D(3) : | 76.4 |
| RSI | RSI(14): 79.3 | |||
| 52-week | High : | 70.98 | Low : | 55.09 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AXNX ] has closed Bollinger Bands are 7.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 71.08 - 71.44 | 71.44 - 71.74 |
| Low: | 70.14 - 70.52 | 70.52 - 70.84 |
| Close: | 70.42 - 71.02 | 71.02 - 71.51 |
Fri, 15 Nov 2024
Boston Scientific finalizes $3.7B acquisition of Axonics - MassDevice
Fri, 15 Nov 2024
Boston Scientific Closes Acquisition of Axonics, Inc. - PR Newswire
Thu, 14 Nov 2024
Boston Scientific Acquires Axonics: Strategic $71 Per Share Deal with Big Implications (AXNX Acquisition) - tradingcalendar.com
Thu, 07 Nov 2024
Axonics Inc (AXNX) Q3 2024 Earnings: Revenue Hits $116.2 Million, Surpassing Estimates - GuruFocus
Thu, 07 Nov 2024
Axonics Reports Third Quarter 2024 Financial Results - BioSpace
Tue, 05 Nov 2024
Axonics’ Market Growth Strengthens Boston Scientific’s Future (NASDAQ:AXNX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 51 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 87.2 (%) |
| Shares Short | 3,310 (K) |
| Shares Short P.Month | 3,600 (K) |
| EPS | -0.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13 |
| Profit Margin | -1.4 % |
| Operating Margin | -2.5 % |
| Return on Assets (ttm) | -0.7 % |
| Return on Equity (ttm) | -0.9 % |
| Qtrly Rev. Growth | 24.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 8.45 |
| EBITDA (p.s.) | 0.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 14 (M) |
| Levered Free Cash Flow | 17 (M) |
| PE Ratio | -709.81 |
| PEG Ratio | 0 |
| Price to Book value | 5.46 |
| Price to Sales | 8.39 |
| Price to Cash Flow | 253.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|